Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1949 1
1967 1
1975 1
1977 1
1978 2
1984 3
1985 1
1986 1
1988 2
1989 2
1990 4
1991 7
1992 5
1993 5
1994 8
1995 4
1996 9
1997 5
1998 9
1999 19
2000 10
2001 8
2002 7
2003 3
2004 5
2006 1
2007 1
2009 1
2010 6
2011 6
2012 6
2013 4
2014 3
2015 7
2016 5
2017 4
2018 3
2019 3
2020 1
2021 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Among authors: brugger w. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: brugger w. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Cappuzzo F, et al. Among authors: brugger w. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20. Lancet Oncol. 2010. PMID: 20493771 Clinical Trial.
Dendritic cells in cancer vaccines.
Brossart P, Wirths S, Brugger W, Kanz L. Brossart P, et al. Among authors: brugger w. Exp Hematol. 2001 Nov;29(11):1247-55. doi: 10.1016/s0301-472x(01)00730-5. Exp Hematol. 2001. PMID: 11698120 Free article. Review.
The role of cytokines in oncology.
Lange W, Brugger W, Rosenthal FM, Kanz L, Lindemann A. Lange W, et al. Among authors: brugger w. Int J Cell Cloning. 1991 Jul;9(4):252-73. doi: 10.1002/stem.5530090403. Int J Cell Cloning. 1991. PMID: 1894956 Free article. Review.
Improving outcomes in transplantation.
Brugger W. Brugger W. Semin Oncol. 2002 Apr;29(2 Suppl 6):23-6. doi: 10.1053/sonc.2002.32751. Semin Oncol. 2002. PMID: 12040531 Review.
171 results